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ABSTRACT 
Von Hippel – Lindau disease is a heritable multisystem cancer syndrome that is associated with a germline 
mutation of the VHL tumour suppressor gene on the short arm of chromosome 3. This disorder is not rare (about 
one in 36 000 live births) and is inherited as a highly penetrant autosomal dominant trait (i.e. with a high 
individual risk of disease). Affected individuals are at risk of developing various benign and malignant tumours of 
the central nervous system, kidneys, adrenal glands, pancreas, and reproductive adnexal organs. Because of the 
complexities associated with management of the various types of tumours in this disease, treatment is multi-
disciplinary. 
Objectives:  We present an overview of the clinical aspects, management, and treatment options for von Hippel-
Lindau disease in three families, a total number of 7 patients. 
Study Design:  It was a descriptive observational study. 
Material and Methods:  In this study we included 7 patients belonging to 3 families. In the first family there was 
a father and a son, both of them had Von Hippel-Lindau disease. In the second family two sisters and one brother 
was involved, while in the third family one brother and one sister had this disease. This study was conducted in 
the Department of Neurosurgery, Lahore General Hospital, Lahore. 
Results:  In this study we observed that 1 out of 7 patients died, 1 is bed ridden with paraparesis. The rest 5 
patients are passing their normal routine life. We observed that in all of our patients (100%) there was CNS 
involvement, the recurrence in our series is quite high. (70%), 3 of our patients required permanent V.P. Shunt 
while 1 patient required per operative EVD. In 2 of our patients eye surgery was required. 1 of our patient 
underwent the Gama Knife (Radio surgery). 
Key words:  Von Hippel-Lindau disease, germline mutation, tumour suppressor gene, penetrant autosomal 
dominant trait. 
 
INTRODUCTION 
Von Hippel – Lindau disease is an autosomal domi-
nant neoplasia syndrome that results from a germline 
mutation in the VHL gene.
1-3
 Germline mutations in 
the VHL gene lead to the development of several beni-
gn or malignant tumours, and cysts in many organ sys-
tems. 
 Affected individuals might develop CNS lesions 
including cerebellar, spinal cord, brainstem, nerve 
root, and supratentorial haemangioblastomas, as well 
as retinal haemangioblastomas and endolymphatic sac 
tumours.
2,4
 Visceral features of the disorder include 
renal cysts and carcinomas, phaeochromocytomas, 
pancreatic cysts and neuroendocrine tumours, as well 
as epididymal and broad ligament cystadenomas. Von 
Hippel-Lindau is not rare (incidence is roughly one in 
36 000 live births),
5,6
 and has over 90% penetrance by 
65 years of age.
5
 Before comprehensive screening 
surveys became routine, median survival of patients 
with the disease was less than 50 years of age. 
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 The main causes of death were complications lin-
ked to renal cell carcinomas and CNS haemangio-
blastomas.
7-10
 Improved surveillance, earlier diagnosis 
of lesions by modern imaging and laboratory studies 
(panel 1),
11
 improvements in treatment, and increased 
knowledge of this disease have improved prognosis 
and reduced the complications related to these tumo-
urs. Because of the progressive, diverse nature, and 
high frequency of multiple neoplasms in various organ 
systems, the management of the tumour types is comp-
licated by the presence of others. A multi specialty 
team is needed for the optimum assessment and treat-
ment of these patients. Comprehensive serial screening 
and routine scheduled follow-up are essential for pro-
per care.
11
 
 
Molecular Genetics 
VHL is a tumour suppressor gene on the short arm of 
chromosome 3 (3p25–26).23 Most people with the
disorder inherit a germline mutation of the gene from 
the affected parent, and a normal (wild type) gene 
from the unaffected parent. According to Knudson’s 
two-hit hypothesis of tumorigenesis, initiation of 
tumour formation arises when both VHL alleles are 
inactivated.
24,25
 Germline mutations of VHL are pre-
sent in all the cells of affected individuals who inherit 
the genetic trait. However, only those cells that (1) 
undergo a deletion or mutation of the remaining wild 
type allele, and (2) are constituents of susceptible tar-
get organs. Subsequently, disruption of VHL – protein 
mediated degradation of HIF could contribute to tum-
our formation through multiple mechanisms (Figure 
1). If VHL function were absent or abnormal, HIF 
could stimulate angiogenesis, which is critical for 
persistence of tumours associated with the disorder. 
HIF – mediated angiogenesis could result from incre-
ased levels of VEGF or PDGF Beta, or both, which are 
known to be important for proliferation of endothelial 
cells and pericytes, respectively (Figure 1). This link 
 
 
 
Fig. 1: Interaction of VHL protein with other proteins including elongin B, elongin C and CUL2, to form the VCB – CUL2 
complex. 
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might explain the highly vascular nature of tumours 
associated with von Hippel – Lindau disease, espe-
cially haemangioblastomas and renal cell carcinomas. 
 Moreover, high vascular permeability of the 
tumour vessels, resulting from increased VEGF levels, 
might also underlie the peritumoural oedema and cysts 
generally present in this disorder.
10
 Another potential 
mechanism of HIF – mediated carcinogenesis is 
overproduction of TGF Alpha. Besides being a potent 
mitogenic factor (especially for renal epithelium), 
raised TGF Alpha can stimulate cellular over expres-
sion of epidermal growth factor receptors (receptors 
for TGF Alpha), creating an autocrine loop.
6,22,23–28
 
 Other possible mechanisms of tumorigenesis cau-
sed by absent or abnormal VHL protein, independent 
of HIF, include disruption of normal cell cycle, incre-
ased angiogenesis, and abnormalities in the extra-
cellular matrix. The inability to leave the cell cycle (ie, 
to enter Go) is seen in cells without VHL protein.
24
 
This event might take place early in tumorigenesis. 
Furthermore, mutations of the protein itself could 
increase VEGF expression through incorrect transcrip-
tional and posttranslational regulation.
27,28
 These muta-
tions might augment the angiogenic effects mediated 
by HIF and further increase tumour vessel perme-
ability. Finally, although cells without VHL protein 
can secrete fibronectin, they cannot properly assemble 
a fibronectin extracellular matrix, which could con-
tribute to carcinogenesis.
23
 Overall, HIF – mediated, 
direct VHL protein – mediated, and unknown effects 
of abnormal or absent VHL protein probably interact 
to induce formation of the various tumours in this 
disease. 
 
CLINICAL PRESENTATION 
VHL is associated with tumors in a multitude of 
organs, including the kidney, adrenal gland, CNS, eye, 
inner ear, epididymis, and pancreas. With current ima-
ging modalities and genetic testing, many individuals 
are diagnosed while still asymptomatic. The diagnosis 
continues to be based on clinical criteria. Individuals 
with a family history are considered positive for the 
disease if screening tests diagnose a CNS hemangio-
blastoma (including retinal), pheochromocytoma, or 
renal manifestations. Patients who are diagnosed de 
novo without a family history must have evidence of 
two or more CNS hemangioblastomas or one CNS 
manifestation with a visceral tumor to meet diagnostic 
criteria.
13
 
Central Nervous System Lesions 
Hemangioblastomas are the most common tumor 
found in VHL patients, affecting up to 80% of pati-
ents. The average age of presentation is 33 years,
14
 
these lesions are always benign but may cause signi-
ficant morbidity because of volume effect. These les-
ions may occur anywhere along the craniospinal axis 
and may cause swelling and symptoms based on their 
location along this axis. 
 
Retina 
Retinal hemangioblastomas are very common in VHL 
patients, occurring in 60% of patients.
13
 They may be 
multifocal or bilateral and occur early in life. The 
mean age of diagnosis of retinal hemangioblastomas is 
25 years.
13
 They are benign but symptomatic and may 
lead to vision loss. 
 
Inner Ear 
Occurring in 11% of VHL patients, endolymphatic sac 
tumors are not as common as other CNS manifes-
tations of VHL. They may lead to hearing loss and 
problems with equilibrium.
15
 
 
Visceral Lesions 
Kidneys 
VHL patients are prone to both renal cystic disease 
and solid lesions of the kidneys. RCC, which may be 
malignant, occurs in 25% to 45% of VHL patients.
13
 
VHL may also be associated with renal cysts that do 
not have a malignant potential but may cause local 
effects. Sixty percent of VHL patients have some renal 
manifestation.
13
 Because of its malignant potential, 
RCC is a significant cause of death in VHL patients, 
and when left untreated, it can lead to death from 
metastases in 13% to 42% of patients.
16,17
 These renal 
manifestations may be multifocal and bilateral, includ-
ing bilateral RCCs. 
 The mean age of presentation for renal manifes-
tations is 39 years. 
 
Adrenal Glands 
Pheochromocytomas occur in up to 20% of patients 
with VHL disease. These may be multiple as well as 
bilateral and may occur as extra-adrenal lesions as 
paragangliomas.
13
 They occur at a mean age of 30 
years. 
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Pancreas 
Most of the pancreatic lesions associated with VHL 
are cystic and are classified histologically as serous 
cystadenomas. These cystic lesions may occur as a 
single lesion or as multiple lesions and occur in 17% 
to 56% of patients with VHL.
18,19
 These lesions have 
no malignant potential but may replace enough of the 
pancreas to cause endocrine or exocrine insufficiency 
of the pancreas or compression of the intestine or the 
bile duct. Solid lesions are also linked to VHL. Pan-
creatic neuroendocrinetumors (PNETs), which are 
always nonfunctional, have a malignant potential. 
PNETs have been previously reported to be present in 
12% to 17% of patients with VHL, and these tumors 
behave in a malignant fashion in up to 17% of patients. 
Despite their malignant potential, they remain an un-
common cause of death.
20
 An association between 
PNETs and pheochromocytoma has been reported.
21
 
 
Epididymis and Broad Ligament 
Cystadenomas 
Broad ligament cystadenomas have been reported in 
women with VHL. 
 Epididymal cystadenomas are benign and typically 
asymptomatic but may occur in up to 60% of patients 
with VHL. 
 
Clinical Diagnosis 
Diagnosis of von Hippel – Lindau disease is often 
based on clinical criteria. Patients with a family his-
tory, and a CNS haemangioblastoma (including retinal 
haemangioblastomas), phaeochromocytoma, or clear 
cell renal carcinoma are diagnosed with the disease. 
Those with no relevant family history must have two 
or more CNS haemangioblastomas, or one CNS hae-
mangioblastoma and a visceral tumour (with the 
exception of epididymal and renal cysts, which are 
frequent in the general population) to meet the 
diagnostic criteria.
9
 Specific correlations of genotype 
and phenotype have emerged in affected families. 
Several familial phenotypes of von Hippel-Lindau 
disease are now recognized, providing useful informa-
tion to screen and counsel affected individuals (panel 
2). Type 1 families have a greatly reduced risk of pha-
eochromocytomas, but can develop all the other tum-
our types generally associated with the disease. Type 2 
families have phaeochromocytomas, but have either a 
low – risk (type 2A) or high-risk (type 2B) for renal 
cell carcinomas. Type 2C families have phaeochromo-
cytomas only, with no other neoplastic findings of 
VHL (panel 2). 
 
Adapted from reference 11. Imaging techniques 
that are generally recommended before and after 
contrast infusion 
 
Type I 
Retinal haemangioblastomas 
CNS haemangioblastomas 
Renal cell carcinoma 
Pancreatic neoplasms and cysts 
Type II A 
Phaeochromocytomas 
Retinal haemangioblastomas 
CNS haemangioblastomas 
Type II B 
Phaeochromocytomas 
Retinal haemangioblastomas 
CNS haemangioblastomas 
Renal cell carcinomas 
Pancreatic neoplasms and cysts 
Type II C Phaeochromocytoma only 
 
 
Panel 1: Recommended Intervals for Screening in At – Risk Individuals 
Test Start age ( Frequency) 
Ophthalmoscopy Infancy (yearly) 
Plasma or 24 h urinary catecholamines and metanephrines 2 years of age (yearly and when blood pressure is raised) 
MRI of craniospinal axis CT and MRI of internal auditory 
canals 
11 years of age (yearly) Onset of symptoms (hearing loss, 
tinnitus, vertigo, or unexplained difficulties of balance) 
Ultrasound of abdomen 8 years of age (yearly; MRI as clinically indicated) 
CT of abdomen 18 years of age or earlier If clinically indicated (yearly) 
Audiological function tests When clinically indicated 
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MATERIAL AND METHODS 
This was a prospective study perfor-
med in the department of Neurosur-
gery Lahore General Hospital over a 
period of 6 years from January 2006 
to January 2012. 
 
RESULTS 
7 patients belonging to 3 families 
were included in this study. The first 
family had involvement of a father 
and his son, both of them had Von 
Hippel – Lindau disease. The second 
family had two sisters and one brother 
having VHL disease. In the third 
family a brother and a sister was the 
victim of this disease. At the first 
admission, we did all neurological 
imaging studies and visceral screen-
ing. Sporadic Hemangioblastomas 
were not included in our study. Oph-
thalmologist, nephrologists / urologist 
were consulted whenever required. 
 
Panel 2: Genotype – phenotype classifications in families with von 
Hippel – Lindau disease. 
 
Site Percentage Sign and Symptoms 
Cerebellum 37 
Gait ataxia (64%), Dysmetria (64%),  
Headaches (12%),  
Diplopia (8%), Vertigo (8%), Emesis (8%) 
Brain stem 10 
Hypaesthesia (55%),  
Gait ataxia (22%), 
Dysphagia (22%),  
Hyper-reflexia (22%), 
Headaches (11%),  
Dysmetria (11%) 
Spinal cord 50 
Hypaesthesia (83%), Weakness (65%), 
Gait ataxia (65%),  
Hyper-reflexia (52%), 
Pain (17%),  
Incontinence (14%) 
 
Frequency of signs and symptoms of patients who were undergoing 
resection.
12
 
 
 
Gender Distribution Total No. of Patients = 7 
4
3
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Figure 2:  Male to Female ratio. 
 
Sub occipital craniectomy was done in all cases. 
 In our study of 7 patients 1 of our patient expired, 
1 of the patient is bed ridden with paraparesis. The re-
maining 5 patients are passing their normal routine 
life. 
 In our study we found that all the 7 patients 
(100%) there was central nervous system involvement. 
In 2 of the patients there was eye involvement, 2 of the 
patients had renal involvement, 1 patient has invol-
vement of the pancreas, one has involvement of the 
spinal cord and 1 has liver involvement as well. The 
recurrence in our series is quite high (70%). 
 In 3 of our patients we had to place permanent 
Ventriculo-peritoneal Shunt while 1 of the patient we 
had to put per-operative extra ventricular drain (EVD). 
 Two of the patients with eye involvement needed 
eye surgery and were referred to the ophthalmology 
department, while 1 patient was sent for Gama Knife 
(Radio surgery). Pre operative symptoms improved in 
all post neurosurgical procedures. There was no 
wound infection in any case. No new neurological 
deficit in any case except transient nasal regurgitation 
in one case which improved at the same hospital 
admission. 
 
DISCUSSION 
In VHL patients might develop CNS lesions including 
cerebellar, spinal cord, brainstem, nerve root, supra-
tentorial haemangioblastomas and endolymphatic sac 
tumours. With the current imaging modalities and 
genetic testing, many individuals are diagnosed while 
still asymptomatic. The diagnosis continues to be 
based on clinical criteria. Individuals with a family 
history are considered positive for the disease if
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Figure 3:  Age distribution at the time of diagnosis. 
 
screening tests diagnose a CNS hemangioblastoma 
(including retinal), pheochromocytoma, or renal mani-
festations. Patients who are diagnosed de novo without 
a family history must have evidence of two or more 
CNS hemangioblastomas or one CNS manifestation 
with a visceral tumor to meet diagnostic criteria. 
 In our study one of our 14 years male patient who-
se father also had a VHL disease presented to us with 
headache, vomiting and ataxia for last 2 months. The 
patient also underwent indirect Argon Laser and 
 
Hemisphere Cerebellar Involvement 
 
Left  63%
Right 37%
 
 
Figure 4:  Cerebellar hemisphere involvement. 
29%
72%
Occurred
Not Occurred
Recurrent
 
Figure 5:  Recurrence of tumor. 
 
Cryo treatment to Lt. Eye 6 years earlier but the 
patient’s vision did not improve. MRI showed cystic 
posterior medulla oblongata space occupying lesion. 
Midline sub occipital craniectomy and excision of 
brain stem lesion was performed. Brain stem biopsy 
was inconclusive; the symptoms of the patient impro-
ved and he was discharged from the hospital. 
 Meanwhile, the patient developed duodenal perfo-
ration and underwent laprotomy. 
 The same patient after a lapse of 3 years again 
presented to our department with spinal cord multiple 
lesions. D1 – D4 Laminectomy and excision of 
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intradural intramedullary tumour was done. Three dark 
grayish nodules with the cyst excised. Biopsy revealed 
Hemangioblastoma. 
 After about 1 year the patient presented with
 
     
 
Figure 6:  MRI Cervico Dorsal spine sagital views. 
 
 
 
Figure 7:  MRI Spine axial view with contrast. 
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Figure 8:  Pre-operative MRI Brain. 
 
    
 
Figure 9:  Tumor excised. 
 
headache, vomiting and lower limb weakness. His 
MRI Brain revealed a posterior fossa cysic lesion. 
Retromastroid Sub-occipital craniectomy was perfor-
med and a large cystic cerebellar lesion with dark 
reddish colored nodule excised. Patient has marked 
improvement of his symptoms. The biopsy report 
turned out to be in the favour of hemangioblastoma. 
 Another 28 years female patient whose brother 
and a sister were also the victim of VHL (brother had 
multiple CNS Hemangioblastoma, sister had multiple 
recurrent CNS Hemangioblastoma) presented to us 
with signs of raised intra cranial pressure and had cere-
bellar Hemangioblastoma on Lt. Side. Retro mastoid 
sub occipital craniectomy on left side was performed 
and excision of the tumour was done. After this sur-
gery the patient did well. 
 When screening of the patient was performed she 
also had a renal, pancreatic and liver cyst obvious on 
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Figure 10:  Post-Operative C.T Scar. 
 
 
 
Figure 11:  Post-Operative picture of the patient. 
 
C.T Scan abdomen. 
 She was operated thrice and ventricular peritoneal 
shunt was also done. 
 After about 2 years the same patient again pre-
sented with right sided cerebellar lesion which was 
 
 
Figure 12:  C.T Scan (Pre-Op). 
 
 
 
Figure 13:  Post Op C.T Scan. 
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Figure 14:  C.T Abdomen showing renal. Hepatic and pancreatic cysts. 
 
     
 
Figure 15:  Pre-op and Post op C.T Scan Brain. 
 
excised by performing sub occipital craniectomy on 
the right side. The histopathology once again revealed 
hemangioblastoma 
 In this study we found that the recurrence of this 
disease is very high as compared to in the international 
studies being conducted on this disease. In our study 
the recurrence was very high 70% as compared to the 
international literature which is about 40%. This might 
be because of the genetic differentiation in this part of 
the world. Choyke PL et al 1995 and Wanebo JE et al 
2003 reported in their studies that haemangioblas-
tomas of the central nervous system are the most com-
mon tumour in von Hippel – Lindau disease, affecting 
60 – 80% of all patients. In our study we have also 
observed almost the same results. In this study one of 
our patients expired because of brain stem involve-
ment and respiratory compromise that is contrary to 
the international literature which shows that the mor-
tality in VHL is mostly because renal failure. 
 
CONCLUSION 
Although cerebellar hemangioblastomas represent a 
management challenge in patients with VHL disease 
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because of there multiplicity, progressive nature and 
association with visceral neoplasm, Resection of 
cerebellar hemangioblastoma is safe, curative and is 
the treatment of choice in most cases. 
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